Nikkei Industry Sector
Pharmaceuticals
Overview
Japan's pharmaceutical sector includes both large domestic-focused drug makers and globally operating biopharmaceutical companies with significant international revenue. The industry combines deep scientific capability with strong regulatory relationships and a large aging domestic patient population that drives consistent baseline demand.
Current Trend
Japanese pharma companies are accelerating globalization through overseas acquisitions, licensing deals, and co-development partnerships—particularly in oncology and rare diseases. Biosimilar manufacturing, leveraging Japan's precision production expertise, is also emerging as a significant growth opportunity as biologic patents expire globally.
Companies in This Sector
9
Today's Avg. Price Change
+1.39%
Simple average of constituent stock price changes vs. previous close. Not a sector index.
Updated: 2026-10-30 (JST)
Position in Japan
Japan is the world's third-largest pharmaceutical market by value, providing a stable and substantial home base. The National Health Insurance system, while exerting downward pricing pressure through biennial drug price revisions, ensures broad market access for approved therapies and a predictable revenue floor.
Latest Press Releases
01
Oct
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-09-30 Sumitomo Pharma Co.,Ltd. “Preliminary report on the final analysis results of the European Phase 1 trial of a novel universal influenza vaccine candidate using a novel TLR7 vaccine adjuvant (DSP-0546) created by Sumitomo Pharma.”
30
Sep
Eisai Co.,Ltd. JP3160400002
2026-09-29 Eisai Co.,Ltd. “Eisai Co., Ltd.: Personnel changes and organizational restructuring.”
30
Sep
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-09-29 CHUGAI PHARMACEUTICAL CO.,LTD. “Chugai Pharmaceutical and InxMed have entered into a worldwide licensing agreement regarding the RAF-MEK molecular adhesive SPYK04.”
30
Sep
Shionogi & Co.,Ltd. JP3347200002
2026-09-29 Shionogi & Co.,Ltd. “We have published our Integrated Report 2026.”
29
Sep
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-09-28 DAIICHI SANKYO COMPANY,LIMITED “Regarding the voluntary withdrawal of the US application for approval of ifinatamab deruxtecan (I-DXd/DS-7300) for advanced small cell lung cancer (291.1KB) PDF file will be displayed in a new window.”
29
Sep
Eisai Co.,Ltd. JP3160400002
2026-09-28 Eisai Co.,Ltd. “The combination therapy of Lenvima® (lenvatinib) and Wellireg® (verzutifan) has been approved by the U.S. FDA for adult patients with previously treated advanced clear cell renal cell carcinoma. This approval is based on the results of the Phase III clinical trial "LITESPARK-011," which evaluated the combination therapy of Lenvima and Wellireg compared to cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC) who had previously received treatment with PD-1/PD-L1 inhibitors. The combination of Lenvima and Wellireg is the first combination therapy of a multi-target VEGFR tyrosine kinase inhibitor and an HIF-2α inhibitor to be approved in ccRCC patients.”
29
Sep
Eisai Co.,Ltd. JP3160400002
2026-09-28 Eisai Co.,Ltd. “8,250 drinking cups donated to support lymphatic filariasis control efforts in Papua New Guinea—through an employee-participation "One-Coin Donation" project, in collaboration with JICA and Toyota Tsusho (PNG) Ltd., supporting local health and medical activities.”
29
Sep
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-09-28 CHUGAI PHARMACEUTICAL CO.,LTD. “Announcement regarding the discontinuation of obesity treatment development for GYM329 (emugrobart), the return of licenses, and the resumption of SMA development.”
29
Sep
Shionogi & Co.,Ltd. JP3347200002
2026-09-28 Shionogi & Co.,Ltd. “Regarding the European approval of the anti-coronavirus drug encitrelvir fumarate for post-exposure prevention of COVID-19.”
26
Sep
Otsuka Holdings Co.,Ltd. JP3188220002
2026-09-25 Otsuka Holdings Co.,Ltd. “Notice of price revisions for some products – effective for deliveries from January 1st, 2027 (Friday).”
26
Sep
Shionogi & Co.,Ltd. JP3347200002
2026-09-25 Shionogi & Co.,Ltd. “Notice of relocation of our Tokyo Nihonbashi office.”
25
Sep
Otsuka Holdings Co.,Ltd. JP3188220002
2026-09-24 Otsuka Holdings Co.,Ltd. “Additional analysis results from the Phase 3b trial of the attention-deficit/hyperactivity disorder (ADHD) treatment drug "SIMTRIYO® (centanafazine)" were presented at Psych Congress 2026.”
25
Sep
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-09-24 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approval of trastuzumab deruxtecan (T-DXd/DS-8201) for postoperative drug therapy for HER2-positive early breast cancer (256.5KB) will open in a new window as a PDF file.”
25
Sep
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-09-24 CHUGAI PHARMACEUTICAL CO.,LTD. “Roche's announcement regarding cefaxelcene sodium (interim analysis results from the Phase III IMAGINATION trial).”
25
Sep
Astellas Pharma Inc. JP3942400007
2026-09-24 Astellas Pharma Inc. “An international collaborative Phase III trial has been initiated in patients with advanced non-small cell lung cancer who are KRAS G12D mutation-positive and have a history of setidegrasib treatment.”
23
Sep
Otsuka Holdings Co.,Ltd. JP3188220002
2026-09-22 Otsuka Holdings Co.,Ltd. “Positive results from a Phase 3 trial of urefnersen for amyotrophic lateral sclerosis (ALS) caused by FUS mutations – a steady step forward towards realizing gene-targeted therapy for FUS-ALS patients.”
19
Sep
Otsuka Holdings Co.,Ltd. JP3188220002
2026-09-18 Otsuka Holdings Co.,Ltd. “FACEDUO has launched new content titled "Understanding a New Perspective on Dementia."”
19
Sep
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-09-18 CHUGAI PHARMACEUTICAL CO.,LTD. “FoundationOne CDx cancer genome profiling has been approved as a companion diagnostic for lorlatinib in ALK fusion gene-positive non-small cell lung cancer.”
19
Sep
Astellas Pharma Inc. JP3942400007
2026-09-18 Astellas Pharma Inc. “The European CHMP has adopted a recommendation for marketing authorization of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in combination with pembrolizumab for cisplatin-treated muscle-invasive bladder cancer.”
18
Sep
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-09-17 CHUGAI PHARMACEUTICAL CO.,LTD. “Roche's announcement regarding Lunsmio (data from the international collaborative Phase III CELESTIMO trial for relapsed or refractory follicular lymphoma).”